EU Proposal To Address Impact Of Duplicate Marketing Authorizations On Biosimilars Availability
The European Commission has proposed updating its guidance on duplicate marketing authorizations to address concerns regarding the availability of biosimilars.
You may also be interested in...
The European Commission has issued a revised note on how it handles requests from pharmaceutical companies for duplicate marketing authorisations1,2. The revised note, among other things, attempts to clarify a misunderstanding by applicants of the term "true duplicate" in the March 2010 version of the document3,4.
Remote inspections are here to stay, and global regulators are aligning efforts to develop consensus on how these should be conducted.
Device companies operating in Canada are being advised to review their internal procedures in anticipation of new postmarket requirements that come into force this year.